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Summary
Background.— Sex hormones and gender differences are associated with the occurrence of
ventricular arrhythmias.
Aim.— To investigate the relationship between sex hormones and idiopathic outﬂow tract ven-
tricular arrhythmias (IOTVA), and the effect of oestrogen replacement therapy on IOTVA, in
postmenopausal female patients.
Methods.— Plasma sex hormone concentrations and ventricular arrhythmia counts were esti-
mated in postmenopausal patients with IOTVA and control postmenopausal women. The effect
of oestrogen replacement therapy on IOTVA was observed in postmenopausal patients with
IOTVA.
Results.— The concentration of oestradiol in postmenopausal patients with IOTVA was sig-
niﬁcantly lower than that in control postmenopausal women (8.4± 3.4 vs 36.9± 12.8 pg/mL,
respectively; P < 0.001). The ventricular arrhythmia count in postmenopausal patients with
IOTVA was signiﬁcantly higher than that in controls (10,171± 6091 vs 209± 468 counts/24 hours,
respectively; P < 0.001). After 3 months of oestrogen replacement therapy, the ventricular
arrhythmia count was signiﬁcantly lower than that before therapy (3958± 1972 vs 10171± 6091
counts/24 hours, respectively; P < 0.001).
Abbreviations: IOTVA, idiopathic outﬂow tract ventricular arrhythmias; LVOT, left ventricular outﬂow tract; PVC, premature ventricular
ontraction; RVOT, right ventricular outﬂow tract.
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Conclusion.— This study showed that the concentration of oestradiol was lower
in postmenopausal patients with IOTVA than in control postmenopausal women,
and that oestrogen replacement therapy can inhibit effectively the genesis of
IOTVA.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— Les hormones sexuelles et le sexe sont associés à la survenue d’arythmies
ventriculaires.
Objectif.— Évaluer les relations entre le taux d’hormones sexuelles et la survenue d’arythmies
ventriculaires idiopathiques naissant de la chambre de chasse ventriculaire gauche (IOTVA),
ainsi que les excès d’un traitement estrogénique substitutif sur la survenue de ces arythmies
ventriculaires chez des femmes ménopausées.
Méthode.— Les concentrations plasmatiques d’hormones sexuelles, et le comptage
des arythmies ventriculaires ont été estimés chez des femmes ménopausées ayant
des arythmies ventriculaires idiopathiques (IOTVA), et comparés à des femmes
ménopausées témoins. L’effet du traitement estrogénique substitutif sur les IOTVA a
été observé chez des femmes ménopausées, et présentant de telles arythmies ventricu-
laires.
Résultat.— Le taux d’œstradiol chez des femmes ménopausées ayant des IOTVA est
signiﬁcativement moindre comparativement aux femmes ménopausées témoins (8,4± 3,4 vs
36,9± 12,8 pg/mL, respectivement ; p < 0,001). Le taux d’arythmie ventriculaire chez les
femmes ménopausées avec IOTVA était signiﬁcativement plus élevé que chez les témoins
(10,171± 6091 vs 209± 468 coups/24 heures, respectivement ; p < 0,001). Après trois mois de
traitement estrogénique substitutif, le taux d’arythmie ventriculaire était signiﬁcativement
moindre qu’avant traitement (3958± 1972 vs 10,171± 6091 coups/24 heures, respectivement ;
p < 0,001).
Conclusion.— Cette étude montre que le taux d’œstradiol est moindre chez les femmes
ménopausées ayant des arythmies ventriculaires idiopathiques (IOTVA) comparativement à
des femmes ménopausées témoins et qu’un traitement estrogénique substitutif peut inhiber
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Background
Ventricular tachycardia or frequent PVCs arising from
the left and right ventricular outﬂow tracts in patients
without apparent structural heart disease are called idio-
pathic outﬂow tract ventricular arrhythmias. Women have
a higher prevalence of idiopathic right outﬂow tract ven-
tricular arrhythmias, while men have a higher prevalence
of idiopathic left outﬂow tract ventricular arrhythmias
[1,2].
Sex hormones and gender differences have been
reported be associated with the occurrence of ventric-
ular arrhythmias [3—6]. Our previous study showed that
the concentration of oestradiol in male patients with
IOTVA was signiﬁcantly decreased. In addition, we found
that the ventricular arrhythmia count was signiﬁcantly
negatively correlated with the concentration of oestra-
diol in male patients with IOTVA [7]. However, the
changes in sex hormone concentrations in postmenopausal
female patients with IOTVA, and the effect of oestro-
gen replacement therapy on IOTVA, remain unknown.
In the present study, we investigated the relationship
between sex hormones and IOTVA, and the effect of oestro-
gen replacement therapy on IOTVA, in postmenopausal
women.
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atients and methods
tudy population and data collection
his clinical protocol was approved by the institutional med-
cal ethics committee and was conducted according to the
thical guidelines outlined in the Declaration of Helsinki. We
valuated 35 consecutive postmenopausal female patients
ith IOTVA who agreed to participate in the study. The
articipants received oestrogen replacement therapy (con-
ugated equine oestrogen, 0.625mg/day for 3 months)
rom Renmin Hospital of Wuhan University. Thirty-ﬁve age-
atched postmenopausal women without IOTVA who also
greed to participate in the study were used as a con-
rol group; these women were selected randomly from the
unicipal population registry in Wuhan City. Both groups
nderwent the following tests: physical examination; chest
-ray; laboratory values; echocardiography with wall motion
nalysis; electrophysiological study and/or 12-lead elec-
rocardiographic monitoring to exclude others types of
rrhythmia; and Doppler screening to exclude the pres-
nce of structural heart disease. Potential participants were
xcluded if they were aged > 70 years, had a disease other
han IOTVA (including fever, coronary artery disease, oth-
rs types of arrhythmia, hypertension, endocrine secretion,
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Table 1 Characteristics of postmenopausal women with and without idiopathic outﬂow tract ventricular arrhythmias.
Characteristic Control
(n = 35)
IOTVA
(n = 35)
Age (years) 55± 5 54± 5
Smokers (% of patients) 0.0 2.9
Alcohol drinkers (% of
patients)
5.7 2.9
Body mass index (kg/m2) 23.2± 3.2 22.8± 3.6
Ejection fraction (%) 61± 3 62± 3
PVC count (number of
counts/24 hours)
209± 468 1,0171± 6091*
Heart rate (beats/min) 73.7± 8.6 74.6± 9.3
Luteinizing hormone (range)
(mLU/mL)
27.8± 8.9 (9.4—40.1) 24.3± 9.6 (11.2—39.2)
Progestogen (range) (ng/mL) 0.49± 0.19 (0.10—0.67) 0.51± 0.20 (0.12—0.70)
Oestradiol (range) (pg/mL) 36.9± 13.8 (16.7—67.1) 8.4± 3.4* (4.6—12.8)
Potassium (mmol/L) 3.92± 0.17 3.88± 0.20
Sodium (mmol/L) 142.2± 1.7 143.1± 1.8
Calcium (mmol/L) 2.38± 0.18 2.33± 0.19
IOTVA: idiopathic outﬂow tract ventricular arrhythmias; PVC: premature ventricular contraction. Data are mean± standard deviation
unless otherwise indicated. The reference values for luteinizing hormone, progestogen and oestradiol concentrations in healthy
postmenopausal women were 5.0 to 52.3mLU/mL, 0.06 to 0.73 ng/mL and 13.0 to 93.3 pg/mL, respectively.
m
w
t
a
h
p
i
t
G
t
o
l
c
m
t
t
i
o
c
U
r
a
b
E
t
t
l
S
[
S
A
t
t
u
u
m
l
R
C
A
p
m
b
p
h
p
d
o
r* P < 0.05, compared with controls.
etabolic diseases, etc.) or if they had taken anymedication
ithin the previous 2 months.
Blood samples for analysis of basal hormone concen-
rations were obtained between 8:00 am and 9:00 am
fter an overnight fast. Concentrations of plasma sex
ormones (including luteinizing hormone, oestradiol and
rogestogen) were measured using commercially prepared
mmunoassay kits according to the manufacturer’s instruc-
ions (ADVIA Centaur Immunoassay Assay System, Bayer,
ermany). Serum potassium, sodium and calcium concen-
rations were measured with standard laboratory techniques
n a Hitachi 912 Analyzer (Roche Diagnostics, Basel, Switzer-
and). PVCs were deﬁned as identiﬁable premature QRS
omplexes (premature with respect to the P wave). Other
ultipart forms of PVCs, such as bigeminy (two consecu-
ive PVCs), salvos (three consecutive PVCs) and ventricular
achycardia (four or more consecutive PVCs), were all
ncluded in the PVC count. The average PVC count (number
f counts/24 hours) was assessed by 72-h, 12-lead electro-
ardiographic monitoring (GE Healthcare, Milwaukee, WI,
SA). The 12-lead electrocardiogram (ECG) diagnostic crite-
ia for idiopathic right outﬂow tract ventricular arrhythmias
re a wide QRS complex tachycardia with a left bundle
ranch block pattern and an inferior axis [8]. The 12-lead
CG diagnostic criteria for idiopathic left outﬂow tract ven-
ricular arrhythmias are an S wave in lead I and an R-wave
ransition in leads V1 or V2; the absence of an S wave in
eads V5 or V6 suggests a supravalvular location, whereas an
wave in leads V5 and V6 indicates an infravalvular location
9].
t
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t
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wtatistical analysis
ll values were expressed as means± standard deviations or
he percentage of incidence. The chi2 test or Fisher’s exact
est was used to compare proportions. Student’s t test was
sed for comparisons between groups. The paired t test was
sed for comparisons before and after oestrogen replace-
ent therapy. Statistical signiﬁcance was assumed if P was
ess than 0.05.
esults
linical characteristics
s shown in Table 1, there were no differences between
ostmenopausal patients with IOTVA and control post-
enopausal women in terms of mean age (P = 0.99), mean
odymass index (P = 0.86), mean ejection fraction (P = 1.00),
roportion of smokers (P = 1.00) and proportion of alco-
ol drinkers (P = 1.00). In the IOTVA group, 68.6% (24/35)
atients had IOTVA arising from the RVOT. There were no
ifferences in serum concentrations of potassium, sodium
r calcium between the two groups (P = 0.95, 1.00 and 1.00,
espectively). There were no differences in the concen-
rations of luteinizing hormone (P = 0.28) and progestogen
P = 0.58) between the two groups. However, the concen-
ration of oestradiol in postmenopausal patients with IOTVA
as signiﬁcantly lower than that in control postmenopausal
omen (P < 0.001). Most ventricular arrhythmias were shown
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as PVCs; the ventricular arrhythmia count in postmenopausal
patients with IOTVA was signiﬁcantly higher than that in
control postmenopausal women (P < 0.001).
Effect of oestrogen replacement therapy on
ventricular arrhythmias in postmenopausal
patients with idiopathic outﬂow tract
ventricular arrhythmias
After 3 months of oestrogen replacement therapy, post-
menopausal patients with IOTVA had no change in heart
rate compared with before therapy (73.9± 8.9 vs 74.6± 9.3
beats/min, respectively; P = 0.83). However, the ventric-
ular arrhythmia count was signiﬁcantly decreased com-
pared with before therapy (3958± 1972 vs 10,171± 6091
counts/24 hours; P < 0.001).
Discussion
The most common forms of idiopathic ventricular arrhyth-
mias arise from the RVOT; idiopathic ventricular arrhythmias
arising from the LVOT, although less common, are also
observed [1,2]. IOTVA has been demonstrated to have
a unique arrhythmogenic substrate and electropharmaco-
logical proﬁle, including RVOT and LVOT arrhythmias; in
general, these are adrenergically mediated and sensitive to
lower intracellular calcium (e.g. adenosine and verapamil).
Despite disparate sites of origin, previous studies suggest
a common arrhythmogenic mechanism between RVOT and
LVOT arrhythmias, and suggest that arrhythmias from both
of these sites appear to be caused by triggered activity
due to cyclic adenosine monophosphate-mediated, calcium-
dependent, delayed afterdepolarizations [1,2,10,11].
A growing body of evidence has demonstrated that
changes in sex hormone concentrations and gender dif-
ferences may affect ventricular repolarization and may
be associated with the occurrence of ventricular arrhyth-
mias [3—6]. Philp et al. [12] showed that 17-oestradiol
could exert an antiarrhythmic effect via calcium channel
inhibition during myocardial ischaemia. Ullrich et al. [13]
further demonstrated that 17-oestradiol has a calcium
channel inhibitory effect. These results indicated that a
reduction in the 17-oestradiol concentration may exert
a proarrhythmic effect and could lead to calcium channel
activation. In the present study, we found that the concen-
tration of oestradiol, but not of luteinizing hormone and
progestogen, was signiﬁcantly decreased in postmenopausal
patients with IOTVA, which may lead to calcium channel
activation and exertion of a proarrhythmic effect; this is
consistent with the mechanism of IOTVA [1,2,10,11]. In addi-
tion, we found that oestrogen replacement therapy could
inhibit signiﬁcantly the arrhythmia count in postmenopausal
patients with IOTVA. This result further suggested that the
genesis of ventricular arrhythmia was associated with a
reduction in oestradiol concentration in postmenopausal
patients with IOTVA. However, Gokce et al. [14] showed
that oestrogen replacement therapy could increase the fre-
quency of arrhythmia (no statistical signiﬁcance) in healthy
postmenopausal women, which may be attributable to dif-
ferent study conditions (one study was conducted under
[87
hysiological conditions whereas the other was conducted
nder pathological conditions); this needs future study.
ecently, Chen et al. [15] demonstrated that 17-oestradiol
educed vulnerability to ventricular arrhythmia in infracted
ats, indicating that oestrogen may exert an antiarrhythmic
ffect under pathological conditions. These results suggest
hat ‘‘lower oestradiol concentration’’ may be an important
‘substrate’’ for the genesis of IOTVA and that oestrogen
eplacement therapy may have an antiarrhythmic effect.
In conclusion, this study showed that the concentration of
estradiol was reduced in postmenopausal female patients
ith IOTVA compared with in control postmenopausal
omen, and that oestrogen replacement therapy inhibited
ffectively the genesis of IOTVA.
tudy limitation
verall, our study included only a small number of Chinese
atients; a future study with a large cohort will be needed.
he precise mechanism underlying our observation and its
linical relevance require future elucidation.
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